MedTrace Logo

Experience of the Nationwide Gambling Self-exclusion Service Spelpaus - Effects and Limitations of a Unique Harm Reduction Instrument for Problem Gambling

NCT05693155 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-02-09

No results posted yet for this study

Summary

Qualitative interview study addressing the effects and limitations of a unique, government-based, nationwide self-exclusion service for the reduction of gambling-related harm. This service, which allows for individuals at risk of gambling problems (and for anyone) to self-exclude from all licensed gambling in the country, is unique in its nationwide, non-gambling-operator-dependent and multi-operator design. It is a promising tool for the prevention and harm reduction in relation to problem gambling and gambling disorder, but emerging research data report considerable limitations including high access to non-licensed gambling allowing users to breach the voluntary self-exclusion and relapse into hazardous gambling practices. This study will examine effects and limitations of the system, for gamblers and for concerned significant others of gamblers, through qualitative interviews addressing their experience of the system.

Conditions

  • Gambling Disorder
  • Problem Gambling

Interventions

BEHAVIORAL

Voluntary self-exclusion from gambling ('Spelpaus')

Voluntary self-exclusion from gambling, using the government-based, official service 'Spelpaus' (literally 'play break')

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • Region Skane

    lead OTHER

Principal Investigators

  • Anders Håkansson, PhD · Region Skåne

  • Helena Hansson, PhD · Lund University, School of Social Work

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-13
Primary Completion
2023-06-30
Completion
2024-07-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05693155 on ClinicalTrials.gov